These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 7768637

  • 1. Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian-cancer cell lines.
    Nehmé A, Albin N, Caliaro MJ, Guichard S, Jozan S, Julia AM, Bugat R, Canal P.
    Int J Cancer; 1995 May 29; 61(5):643-8. PubMed ID: 7768637
    [Abstract] [Full Text] [Related]

  • 2. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
    Delmastro DA, Li J, Vaisman A, Solle M, Chaney SG.
    Cancer Chemother Pharmacol; 1997 May 29; 39(3):245-53. PubMed ID: 8996528
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells.
    Marth C, Widschwendter M, Kaern J, Jørgensen NP, Windbichler G, Zeimet AG, Tropé C, Daxenbichler G.
    Br J Cancer; 1997 May 29; 76(10):1328-32. PubMed ID: 9374379
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Modulation of cisplatin sensitivity and accumulation by interferon alpha-2A in human squamous carcinoma cell lines.
    Gupta V, Jani JP, Emerson EO, Xu BH, Scalamogna D, Xia H, Katoh A, Zaren HA, Singh SV.
    Int J Cancer; 1995 Nov 03; 63(3):419-22. PubMed ID: 7591242
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG.
    Cancer Res; 1994 Jul 01; 54(13):3500-5. PubMed ID: 8012973
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer.
    Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ, Ozols RF, Fojo AT, Hamilton TC.
    Int J Cancer; 1990 Mar 15; 45(3):416-22. PubMed ID: 2307530
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
    Cheng G, Li Y, Tian F.
    Zhonghua Zhong Liu Za Zhi; 2001 Jul 15; 23(4):305-8. PubMed ID: 11783113
    [Abstract] [Full Text] [Related]

  • 14. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.
    Montopoli M, Bellanda M, Lonardoni F, Ragazzi E, Dorigo P, Froldi G, Mammi S, Caparrotta L.
    Curr Cancer Drug Targets; 2011 Feb 15; 11(2):226-35. PubMed ID: 21158717
    [Abstract] [Full Text] [Related]

  • 15. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T, Masuda H, Naito M, Tamai H.
    Anticancer Res; 2001 Feb 15; 21(4A):2463-9. PubMed ID: 11724308
    [Abstract] [Full Text] [Related]

  • 16. In vitro growth inhibition of cisplatin-resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-gamma by virtue of collateral sensitivity.
    Hong WS, Saijo N, Sasaki Y, Shinkai T, Eguchi K, Sakurai M, Takahashi H, Nakano H, Nakagawa K, Twentyman PR.
    Jpn J Cancer Res; 1987 Nov 15; 78(11):1274-80. PubMed ID: 3121562
    [Abstract] [Full Text] [Related]

  • 17. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts.
    De Pooter CM, Van Oosterom AT, Scalliet PG, Maes RA, de Bruijn EA.
    Biochem Pharmacol; 1996 Mar 08; 51(5):629-34. PubMed ID: 8615899
    [Abstract] [Full Text] [Related]

  • 18. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC.
    Cancer Res; 1994 Nov 15; 54(22):5911-6. PubMed ID: 7954422
    [Abstract] [Full Text] [Related]

  • 19. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
    Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T, Saijo N.
    Cancer Res; 1991 Jun 15; 51(12):3237-42. PubMed ID: 1645616
    [Abstract] [Full Text] [Related]

  • 20. Interferon gamma-induced reduction in erbB-2 tyrosyl phosphorylation in human ovarian carcinoma cells.
    Mishra S, Hamburger AW.
    Int J Cancer; 1994 Aug 15; 58(4):538-42. PubMed ID: 7914514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.